COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 1 of 1 for:    NCT02406833
Previous Study | Return to List | Next Study

Phase I Dose Escalation Study to Investigate the Safety of ISTH0036 in Subjects With Glaucoma Undergoing Trabeculectomy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02406833
Recruitment Status : Completed
First Posted : April 2, 2015
Last Update Posted : February 28, 2018
Information provided by (Responsible Party):
Isarna Therapeutics GmbH

Brief Summary:
This study evaluates the addition of ISTH0036, an antisense oligonucleotide against TGF-β2, to glaucoma filtration surgery (trabeculectomy). The treatment aims at improving the surgery outcome by prevention of excessive scarring and trabecular meshwork transformation.

Condition or disease Intervention/treatment Phase
Primary Open Angle Glaucoma Drug: TGF-β2 antisense oligonucleotide Procedure: Trabeculectomy Phase 1

Detailed Description:

The transforming growth factor beta (TGF-β) is known to play a key role in glaucoma. Increased levels of TGF-β2 in the eye have been linked to trabecular meshwork transformation, increased intraocular pressure and direct optic nerve damage.

Trabeculectomy is the standard surgical intervention to reduce intraocular pressure in subjects no longer sufficiently responding to pressure-lowering medications. Scarring of the surgically opened canal (bleb) often abolishes the effect of trabeculectomy (despite the intraoperative use of Mitomycin C to prevent this). TGF-β2 has been described to play a distinct role in the fibrotic process of bleb closure.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 13 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I, Open-Label, Dose-Escalation Study to Investigate the Safety of ISTH0036, a 'Next Generation' TGF-β2-Selective Antisense Oligonucleotide, in Subjects With Primary Open-Angle Glaucoma Undergoing Trabeculectomy
Actual Study Start Date : April 2015
Actual Primary Completion Date : August 2016
Actual Study Completion Date : August 2017

Arm Intervention/treatment
Experimental: TGF-β2 antisense oligonucleotide

Core Study: Administered intravitreally at the time of trabeculectomy at escalating doses

Post-Study Follow-up: until 1 year after administration

Drug: TGF-β2 antisense oligonucleotide
intravitreal injection
Other Name: ISTH0036

Procedure: Trabeculectomy
Standard trabeculectomy with the use of antimetabolites (mitomycin C) for glaucoma patients with insufficient intraocular pressure (IOP) control

Primary Outcome Measures :
  1. Safety and tolerability as assessed by clinical monitoring and reporting of adverse events (AE) and serious adverse events (SAE) [ Time Frame: 1 year ]

Secondary Outcome Measures :
  1. Intraocular pressure [ Time Frame: 1 year ]
  2. Number of interventions post trabeculectomy [ Time Frame: 1 year ]
  3. Visual field [ Time Frame: 1 year ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subject scheduled for trabeculectomy with Mitomycin C
  • Subject no longer tolerating or benefitting from pharmacologic treatment of glaucoma

Exclusion Criteria:

  • History of relevant ocular trauma < 6 months or ocular infection/inflammation < 3 months
  • severe central visual field loss within 6 months unrelated to glaucoma
  • pregnant or nursing women or subjects not using adequate contraception
  • history or evidence of any other clinically significant disorder, condition or disease that would pose a risk to subject safety or interfere with study evaluations, procedures or interpretation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02406833

Layout table for location information
University Hospital Magdeburg, Ophthalmology
Magdeburg, Germany, 39120
Department of Ophthalmology, Johannes-Gutenberg University Mainz
Mainz, Germany, 55131
University of Tuebingen, Center of Ophthalmology
Tuebingen, Germany, 72076
Sponsors and Collaborators
Isarna Therapeutics GmbH
Layout table for investigator information
Study Director: Petra Fettes, PhD Isarna Therapeutics
Layout table for additonal information
Responsible Party: Isarna Therapeutics GmbH Identifier: NCT02406833    
Other Study ID Numbers: ISTH-01-111
2014-004985-74 ( EudraCT Number )
First Posted: April 2, 2015    Key Record Dates
Last Update Posted: February 28, 2018
Last Verified: February 2018
Keywords provided by Isarna Therapeutics GmbH:
Additional relevant MeSH terms:
Layout table for MeSH terms
Glaucoma, Open-Angle
Ocular Hypertension
Eye Diseases